FAQ on Calidi Biotherapeutics Inc.'s RTNova Platform and IL15 Superagonist Payload

What is the RTNova platform developed by Calidi Biotherapeutics?

The RTNova platform is a systemic antitumor virotherapy platform designed by Calidi Biotherapeutics to treat metastatic cancers by enabling systemic delivery of tumor-targeted virotherapies, enhancing immune response and tumor elimination.

Why is the selection of IL15 superagonist significant for the RTNova platform?

The selection of IL15 superagonist as the first therapeutic payload is significant because preclinical data shows it can be delivered directly into the tumor microenvironment by Calidi’s engineered vaccinia virus, significantly boosting immune response and tumor elimination while minimizing systemic toxicity.

How does the RTNova platform aim to treat metastatic cancers?

The RTNova platform aims to treat metastatic cancers by utilizing engineered vaccinia viruses to deliver therapeutic payloads like the IL15 superagonist directly into the tumor microenvironment, enhancing the immune system’s ability to combat cancer.

What are the potential benefits of Calidi Biotherapeutics’ approach to cancer treatment?

Calidi Biotherapeutics’ approach offers the potential for enhanced efficacy and improved patient safety by protecting, amplifying, and potentiating oncolytic viruses, and targeting disseminated solid tumors to treat or prevent metastatic disease.

Where can I find more information about Calidi Biotherapeutics and its technologies?

For more information about Calidi Biotherapeutics and its technologies, please visit their official website at www.calidibio.com.

What preclinical data supports the efficacy of the RTNova platform with IL15 superagonist?

Preclinical data presented at the AACR Annual Meeting supports the efficacy of the RTNova platform with IL15 superagonist, showing that Calidi’s engineered vaccinia virus can deliver the payload directly into the tumor microenvironment, boosting immune response and tumor elimination.

Who is behind the development of the RTNova platform?

Calidi Biotherapeutics, a company specializing in proprietary technology that empowers the immune system to combat cancer, is behind the development of the RTNova platform. They are headquartered in San Diego, California.

What makes Calidi Biotherapeutics’ stem cell-based platforms novel?

Calidi Biotherapeutics’ stem cell-based platforms are novel because they utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, offering a universal, off-the-shelf solution for cancer treatment.